Among surface molecules expressed on endothelial cells, endoglin (CD105) is emerging as a prime vascular target for antiangiogenetic cancer therapy. CD105 is a cell membrane glycoprotein mainly expressed on endothelial cells and overexpressed on tumor-associated vascular endothelium, which functions as an accessory component of the transforming growth factor -beta receptor complex and is involved in vascular development and remodelling. Quantification of intratumoral microvessel density by CD105 staining and of circulating soluble CD105 has been suggested to have prognostic significance in selected neoplasias. In addition, the potential usefulness of CD105 in tumor imaging and antiangiogenetic therapy has been well documented utilizing different animal models.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/sj.onc.1206813 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Developing a 3D bone model of osteosarcoma to investigate cancer mechanisms and evaluate treatments.
FASEB J
December 2024
Antibody and Vaccine Group, Faculty of Medicine, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton, Southampton, UK.
Osteosarcoma is the most common primary bone cancer, occurring frequently in children and young adults. Patients are treated with surgery and multi-agent chemotherapy, and despite the introduction of mifamurtide in 2011, there has been little improvement in survival for decades. 3-dimensional models offer the potential to understand the complexity of the osteosarcoma tumor microenvironment and aid in developing new treatment approaches.
View Article and Find Full Text PDFCD105-microvessel density analysis and its clinical value in urothelial carcinoma of bladder patients.
Biomarkers
December 2024
Department of Biochemistry, University of Lucknow, Lucknow, India.
Background: Endoglin/CD105-microvessel density (CD105-MVD) is identified as one of the most potential methods for semi-quantification of angiogenesis in human cancer tissues. Present study aimed to examine the diagnosticand prognostic value of CD105-MVD in two clinically distinct subtypes of urothelial carcinoma of bladder (UCB) namely non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) patients.
Methods: Message expression of endoglin was analysed by real-time quantitative polymerase chain reaction (RT-qPCR) and MVD measurement was done by immunohistochemical staining in 90 UCB [NMIBC: 60; MIBC: 30] patients.
Aptamer-functionalized magnetic blade spray coupled with a nucleic acid dye-based mass tag strategy for miniature mass spectrometry analysis of endoglin.
Talanta
February 2025
Chinese Academy of Inspection and Quarantine, Beijing 100176, China. Electronic address:
Ambient ionization mass spectrometry (AIMS) allows rapid analysis of targets, while its overall selectivity is somewhat limited due to the lack of chromatographic separation. Recently, magnetic blade spray (MBS) has enhanced AIMS by incorporating immunomagnetic beads instead of the traditional coated blade spray (CBS) coating, thereby improving selectivity and sensitivity by targeted analyte detection and reducing background interference. In this study, an aptamer-functionalized and nucleic acid dye (GelRed)-loaded MS probe (AGMP) was developed and employed with MBS-based miniature mass spectrometer.
View Article and Find Full Text PDFA systematic review and meta-analysis of the endothelial-immune candidate biomarker endoglin in rheumatic diseases.
Clin Exp Med
November 2024
Department of Biomedical Sciences, University of Sassari, Sassari, Italy.
Existing challenges in accurately diagnosing various rheumatic diseases (RDs) have stimulated the search for novel biomarkers to aid clinical evaluation and monitoring. We conducted a systematic review and meta-analysis of studies investigating the candidate biomarker endoglin (CD105), a transmembrane glycoprotein expressed in endothelial, myeloid, and lymphoid cells, in RD patients and healthy controls. We searched PubMed, Scopus, and Web of Science from inception to 10 August 2024 to identify relevant studies.
View Article and Find Full Text PDFThe vasculogenic mimicry, CD146 and CD105 microvessel density in the prognosis of endometrioid endometrial adenocarcinoma: a single-centre immunohistochemical study.
Biomarkers
November 2024
Department of Biochemistry, School of Life Sciences, University of Sussex, Brighton, UK.
Article Synopsis
- The study focuses on the importance of the microvessel compartment in the tumor environment of endometrioid adenocarcinoma (EA) and explores the implications of vasculogenic mimicry (VM), CD146, and CD105 microvessel density on clinical prognosis.
- A total of 188 EA cases were examined using specific staining techniques, revealing that higher levels of VM channels and CD146/CD105 microvessels were linked to worse prognoses.
- The findings suggest that these factors could serve as independent indicators of prognosis and potential targets for antiangiogenic therapy, although further research is needed for confirmation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!